ClinicalTrials.gg
BiosimilarDrug

BAT1706 clinical trials

Also written BAT1706.

A product of Bevacizumab; its studies count on that page too.

studies test it
4
open now
0
in phase 3
1
first study started
2016

How each study uses BAT1706 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
26 Feb 2004 · AVASTIN · BLA 125085 (FDA, Drugs@FDA; as Bevacizumab)
European Union
12 Jan 2005 · Avastin · EMEA/H/C/000582 (EMA; as Bevacizumab)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

BAT1706 Injection
2

Development codes

BAT1706
3

Studies by the year they started

4 studies that test it; most in 2016 (1)

Studies that test BAT1706, by start year
YearStudies
20161
20171
20211
20231

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
1
Phase 3
1

Who runs them

Industry 4 · Other 0

Bio-Thera Solutions (3) · BeiGene (1)

Often tested with

Tested in the same studies.

Tislelizumab (1)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses BAT1706 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 4

Given beside what is tested · 1 — BAT1706 is usual care or a partner of the new treatment